Mazdutide
ResearchA GLP-1 and glucagon dual receptor agonist from China's Innovent Biologics. Researched for weight loss and type 2 diabetes with promising Phase 3 trial data.
Weight ManagementMetabolic HealthGLP-1 Agonist
Half Life
~7 days
Time to Results
4-12 weeks
Administration
SubQ injection
🐾 Griffin's Research Scorecard
Research Strength
Human Data
Animal Data
Long-Term Data
Beginner Friendly
Storage Difficulty
Injection FrequencyOnce weekly
Cost$$$
🐾 Griffin Says...
Mazdutide is the newer entrant in the dual-agonist GLP-1 space, developed by a Chinese biotech. Phase 3 trials are showing significant weight loss and metabolic improvement. Competes in the same space as tirzepatide but with glucagon instead of GIP as the second receptor.
Benefits
- Weight reduction
- Blood sugar control
- Appetite suppression
- Liver fat reduction
- Dual receptor activity
Best For
- Weight management research
- Metabolic health
- Type 2 diabetes research
Body Systems
MetabolicEndocrineLiver
Mechanisms of Action
- Dual GLP-1 and glucagon receptor agonism
- Enhances fat burning through glucagon pathway
- Reduces appetite via GLP-1
- Weekly dosing schedule
Side Effects
| Effect | Frequency | Severity |
|---|---|---|
| Nausea | Common | Mild |
| Vomiting | Uncommon | Mild |
| Diarrhea | Common | Mild |
Contraindications
Similar precautions to other GLP-1 agonists, not yet approved
Peptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open Calculator